Get the Stockscreener App
4.18
1.88%
-0.08
Codexis Inc stock is traded at $4.18, with a volume of 671.47K.
It is down -1.88% in the last 24 hours and down -17.23% over the past month.
Codexis Inc is a provider of enzymatic solutions for efficient and scalable therapeutics manufacturing that leverages its proprietary CodeEvolver technology platform to discover, develop and enhance novel, high-performance enzymes. Codexis enzymes solve challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis' enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications.
See More
Previous Close:
$4.26
Open:
$4.32
24h Volume:
671.47K
Relative Volume:
0.99
Market Cap:
$340.16M
Revenue:
$70.14M
Net Income/Loss:
$-76.24M
P/E Ratio:
-3.7658
EPS:
-1.11
Net Cash Flow:
$-57.06M
1W Performance:
-3.02%
1M Performance:
-17.23%
6M Performance:
+39.33%
1Y Performance:
+46.67%
1-Day Range:
$4.16
$4.46
1-Week Range:
$4.14
$4.46
52-Week Range:
$2.56
$6.08
Codexis Inc Stock (CDXS) Company Profile
Name
Codexis Inc
Sector
Industry
Phone
650-421-8100
Address
200 PENOBSCOT DRIVE, REDWOOD CITY, CA
Compare CDXS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CDXS
Codexis Inc
|
4.18 | 340.16M | 70.14M | -76.24M | -57.06M | -1.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Codexis Inc Stock (CDXS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-19-24 | Downgrade | The Benchmark Company | Buy → Hold |
| Jun-03-24 | Resumed | Jefferies | Buy |
| May-30-24 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-29-24 | Upgrade | The Benchmark Company | Hold → Buy |
| Nov-07-23 | Downgrade | The Benchmark Company | Buy → Hold |
| Aug-07-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| May-09-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Mar-31-22 | Resumed | Piper Sandler | Overweight |
| Mar-02-22 | Resumed | Cowen | Outperform |
| Apr-12-21 | Initiated | Piper Sandler | Overweight |
| Mar-01-21 | Initiated | Stifel | Buy |
| Feb-26-21 | Reiterated | H.C. Wainwright | Buy |
| Mar-10-20 | Initiated | The Benchmark Company | Buy |
| Jan-17-19 | Upgrade | First Analysis Sec | Neutral → Outperform |
| May-16-18 | Initiated | Stephens | Overweight |
| Oct-13-17 | Reiterated | H.C. Wainwright | Buy |
| May-31-17 | Initiated | Jefferies | Buy |
| Jan-26-17 | Downgrade | First Analysis Sec | Overweight → Equal-Weight |
| Jan-04-17 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Jan-06-16 | Initiated | H.C. Wainwright | Buy |
View All
Codexis Inc Stock (CDXS) Latest News
Specialty Enzymes Market to Expand at 7.5% CAGR, Reaching USD 10.7 Billion by 2032 | SNS Insider - GlobeNewswire Inc.
Codexis announces the approval of equity grants for new employees - MSN
Codexis to Participate in TD Cowen 45th Annual Health Care Conference - The Manila Times
Jordan Seigel - The Globe and Mail
Exclusive: Codexis Unveils Future Roadmap at Major Healthcare Conference - StockTitan
Baillie Gifford & Co. Sells 119,775 Shares of Codexis, Inc. (NASDAQ:CDXS) - MarketBeat
Synthetic Biology Market Top Companies StudyBota Biosciences - openPR
abrdn plc Reduces Stake in Codexis, Inc. (NASDAQ:CDXS) - MarketBeat
Codexis Announces New Employment Inducement Grants - GlobeNewswire
Strategic Talent Investment: Codexis Awards 66.5K Shares in Employee Equity Package - StockTitan
Codexis, Inc. to Report Fourth Quarter and Fiscal Year 2024 Financial Results on February 27, 2025 - Nasdaq
Codexis to Report Fourth Quarter and Fiscal Year 2024 Financial Results on February 27th - GlobeNewswire
Codexis sees $205,481 stock purchase by Opaleye management By Investing.com - Investing.com South Africa
Codexis sees $205,481 stock purchase by Opaleye management - MSN
Codexis Earnings Alert: Critical Q4 & Full Year Results Coming February 27 - StockTitan
Codexis strengthens board with biotech veteran Arthur Levin - MSN
Codexis strengthens board with biotech veteran Arthur Levin By Investing.com - Investing.com Nigeria
Codexis, Inc. Appoints Dr. Arthur Levin to Strategic Advisory Board to Enhance Oligonucleotide Expertise - Nasdaq
Codexis Appoints Arthur Levin, PhD, to Strategic Advisory Board - GlobeNewswire
RNA Drug Development Pioneer Joins Codexis: Oligonucleotide Expert Who Created First Approved Antisense Drugs - StockTitan
Codexis (NASDAQ:CDXS) investors are sitting on a loss of 79% if they invested three years ago - Yahoo Finance
Codexis, Inc. (NASDAQ:CDXS) Sees Large Increase in Short Interest - MarketBeat
Taking a Closer Look At Codexis Inc (CDXS) Following Its Recent Trade - Knox Daily
Can you now get a good deal on Codexis Inc’s shares? - US Post News
Biocatalysis Market is Projected to Increase at a CAGR of 5.2% - openPR
Ratio Revelations: Codexis Inc (CDXS)’s Financial Metrics in the Spotlight - The Dwinnex
Institutional investors in Codexis, Inc. (NASDAQ:CDXS) see US$59m decrease in market cap last week, although long-term gains have benefitted them. - Simply Wall St
5 "Best" Publicly Traded Synthetic Biology Companies - Securities.io
Codexis, Inc. to Host Earnings Call - ACCESS Newswire
Inspire Investing LLC Takes $405,000 Position in Codexis, Inc. (NASDAQ:CDXS) - MarketBeat
Codexis, Inc. (NASDAQ:CDXS) Shares Sold by Assenagon Asset Management S.A. - Defense World
Assenagon Asset Management S.A. Has $1.37 Million Stock Position in Codexis, Inc. (NASDAQ:CDXS) - MarketBeat
Cantor Fitzgerald Forecasts Codexis FY2025 Earnings - Defense World
Cantor Fitzgerald Comments on Codexis FY2025 Earnings - MarketBeat
Codexis expands board with new director Christos Richards - MSN
Codexis, Inc. (NASDAQ:CDXS) Sees Significant Increase in Short Interest - MarketBeat
Codexis expands board with new director Christos Richards By Investing.com - Investing.com Australia
Tallon Kerry Patrick Purchases New Position in Codexis, Inc. (NASDAQ:CDXS) - MarketBeat
Barclays PLC Purchases 70,255 Shares of Codexis, Inc. (NASDAQ:CDXS) - Defense World
Barclays PLC Has $640,000 Stock Holdings in Codexis, Inc. (NASDAQ:CDXS) - MarketBeat
Codexis Appoints Christos Richards to Board of Directors - Taiwan News
Codexis appoints new independent director By Investing.com - Investing.com Australia
Codexis, Inc. Appoints Christos Richards to Board of Directors -January 16, 2025 at 04:05 pm EST - Marketscreener.com
Codexis appoints new independent director - Investing.com India
Codexis Strengthens Board with Life Sciences Veteran Christos Richards, Expert in 450+ Executive Placements - StockTitan
Codexis Inc Stock (CDXS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.27%
3.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):